Mespere LifeSciences
PrivateLast Round
Accelerator
Apr 28, 2014
Company Overview
Mespere LifeSciences is a medical device company that develops non-invasive, integrated hemodynamic monitoring solutions for cardiac and neuro applications.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Sensors, Health IoT
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mespere LifeSciences Comparables
Compare Mespere LifeSciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Noninvasix | 88% | |
| Osypka Medical GmbH | 83% | |
| CNSystems Medizintechnik | 79% | |
Mespere LifeSciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Apr 28, 2014 |
Mespere LifeSciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Accelerator Centre | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 3, 2025
Grew 25% QoQ, from 12 to 15 employees.
- May 1, 2025
Monthly visitors grew 450% MoM, reaching 3.9K.
Mespere LifeSciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Mespere LifeSciences's valuation, stock price, and market status.